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Combination vaccines represent a valuable technological innova-
tion in the field of infectious disease prevention and public health, 
because of their great health and economic value from the indi-
vidual, societal, and healthcare system perspectives.
In order to increase parents’ and healthcare professionals’ con-
fidence in the vaccination programs and maintain their benefits 
to society, more information about the benefits of innovative vac-
cination tools such as combination vaccines is needed.
Purpose of this work is an examination of available hexavalent vac-
cines, that protect against Diphtheria, Tetanus, Pertussis, Poliomy-
elitis, Hepatitis B and Haemophilus influenzae type b infections. 
From the epidemiological updates of vaccine preventable diseases 
to the vaccine development cycle, from the immunogenicity of anti-
genic components to the safety and co-administration with other 
vaccines, several aspects of available hexavalent vaccines are dis-
cussed and deepened.
Also a number of practical considerations on schedules, age of 
employment, strategies for vaccination recovery, vaccination in 
at-risk births are issued, based on the recommendations of Ital-
ian Ministry of Health, Italian Society of Pharmacology (SIF), 
Italian Society for Pediatrics (SIP), Italian Federation of Family 
Paediatricians (FIMP) and Italian Society of Hygiene, Preventive 
Medicine and Public Health (SItI).
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Summary
Introduction
Since the very early vaccines formulation, increasingly 
important targets have been reached in prevention area. 
Nowadays, vaccinations are one of the most relevant 
resource in Public Health, providing prevention against 
diseases once cause of epidemics [1].
Recently, thanks to combination vaccines usage, other im-
portant targets have been achieved. In fact, combination 
vaccines ensure in a single injection a multiple immuniza-
tion [2]. Reduction in the number of administrations leads 
to a decrease in ambulatory accesses and to a better safety 
profile of vaccinations programs, given the fact that a sig-
nificant proportion of adverse events following immuni-
zation (AEFI) results from the act of injection. Combina-
tion vaccines availability is therefore an important tool in 
achieving a safe and successful protection against numer-
ous pathogens, simplifying prospective introduction of 
new vaccines in a less crowded vaccine schedule [3, 4].
Combination vaccines usage provides a relevant value to 
health, with positive effects in the people health with a 
social and economic saving (Fig. 1) [5].
Purpose of this work is an examination of hexavalent 
vaccines, that protect against Diphtheria, Tetanus, Per-
tussis, Poliomyelitis, Hepatitis B and Haemophilus in-
fluenzae type b (Hib) infections.
Hexavalent vaccines development cycle: 
from manufacturing to delivery
Hexavalent vaccines development is time-consuming 
and complex, and passes through the production of sin-
gles vaccines providing Diphtheria, Tetanus and Pertus-
sis antigens (dTaP). Several quality controls are applied 
in every development cycle phase, so that efficacy and 
safety profiles have been raising over the years. The 
first phase is 12-years-long on average and includes the 
pre-clinical and clinical stages, the regulatory agencies 
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registration, and the discharge of the first approved and 
deliverable vaccine batch; within this time vaccine for-
mulation are continually tested in order to provide the 
definitive composition and to develop adequate pro-
duction systems. The second phase is no more than 
36-months-long for the hexavalent vaccines develop-
ment, and includes the production stage; up to 70% of 
this time is devoted to quality controls; the remaining 
time is required for antigens, carriers and adjuvants pro-
cessing and combination, to the achievement of the hex-
avalent composition. Hence the hexavalent vaccine is in 
accordance with the highest standards in pharmaceutical 
industry, in terms of efficacy and safety [6, 7].
During the vaccine development cycle, that is long and 
elaborate, it’s possible a vaccine batch doesn’t pass 
quality control check; this may due, for example, to 
inadequate antigenic concentrations or to an unstable 
formulation. In this scenario, the whole hexavalent com-
bination is stopped and not utilized, even if the quality 
control check failure is related only to a single antigen. 
Hence, it could be necessary a 2-years-long time to re-
store the production standards, with the consequence of 
supplies delivery deficiencies. Pharmaceutical factories 
are dealing with those challenges: if we consider the pro-
duction stages timing, it’s necessary that supplies varia-
tions and vaccines demands will ideally be made with a 
3-years advance in order to maintain an adequate avail-
ability [6, 7].
Details about antigens preparation processing and tim-
ing, and about their formulation in the hexavalent vac-
cines, are described in Figure 2.
In addition to quality assessment, complexity and het-
erogeneity of different regulatory systems amongst 
countries is another relevant challenge in vaccines pro-
duction, since it dictates another time delay to the final 
vaccines availability. Particularly, marketing and import 
authorization of vaccines lots are main critical issues in 
this context [6, 7].
Hexavalent vaccine preventable diseases: 
epidemiological notions
Due to vaccinations introduction, a considerable num-
ber of diseases have been controlled and avoided. Those 
diseases comprehend Diphtheria, Tetanus, Pertussis, Po-
liomyelitis, Hepatitis B and Hib infections, for whom 
immunization can be reached in a single vaccine admin-
istration, hexavalent vaccine [8].
In order to get the best control and prevention of four 
of these diseases (Diphtheria, Tetanus, Pertussis and 
Poliomyelitis), booster vaccinations are necessary, as 
Fig. 1. Combination vaccines usage: a public health, economic and social value.
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required by 2017-2019 Italian National Vaccine Preven-
tion Plan (PNPV) [9]: (i) dTaP-IPV vaccination (pediat-
ric vaccine with a full antigenic amount) in 6-years-old 
children; (ii) dTap-IPV vaccination (adult vaccine with a 
low antigenic amount) in 12 to 19-years-old subjects and 
(iii) dTap vaccination (adult vaccine with a low antigenic 
amount) every 10 years in adult age.
Thanks to such strategies, a significant reduction in epi-
demiological trends of these diseases have been reached 
(Tab. I).
Diphtheria
An increasing reduction in Diphtheria cases in Eu-
rope, from 42/100000 population in 2008 to less than 
0.1/100000 population in 2015, is documented in last 
ECDC Report [10]. Two cases of Diphtheria were none-
theless reported in Spain and Belgium [11].
In Italy, Diphtheria incidence had a dramatically reduc-
tion, up to 0 events in the 2010-2013 period. In the 2015-
2017 period, nonetheless, 8 Diphtheria cases were report-
ed. In particular, one C. Diphtheriae strain was a toxin-
producer, responsible of cutaneous diphtheria, while other 
cases were caused by a non-toxin producer strain [12].
Even in countries where diphtheria is not endemic, 
thanks to high vaccination coverages, risk should not be 
underestimated. Some C. Diphtheriae toxin-gene-free 
strains can colonize nasopharynx and then cause phar-
yngitis, bacteraemias, endocarditis, septic arthritis, ab-
scesses and pneumonia. The presence of non-toxigenic 
Fig. 2. Quality controls performed within the different hexavalent vaccines production stages.
Tab. I. Italian epidemiology of hexavalent vaccine preventable diseases: a comparison before and after vaccine introduction [16].
Disease Notified case number (on average) 
every year, before vaccinations
Notified case number (on average) 
in the period 2010-2013
% Reduction
Diphtheria 7000 0 100%
Tetanus 700 60 – 91.4%
Pertussis 21000 509 – 97.6%
Poliomyelitis 2000 0 100%
Hepatitis B 3000 419 – 86.0%
Haemophilus influenzae type b 69 6 – 91.3%
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C. Diphtheriae strains has been recently documented in 
United States and in Europe, Italy included. Uncom-
monly, some of these strains are armed with toxin genes 
and could start producing the toxin through spontaneous 
reversion to toxigen strain or homologous recombina-
tion among different corynebacteriophages [13, 14].
Tetanus
Even though Tetanus is a preventable disease, several 
cases occur in Italy each year, with the highest notifi-
cation and hospitalization rates compared to other Eu-
ropean countries and other high-income countries. In 
2014, in the last ECDC Report, 84 events were reported 
in Europe, of which 48 confirmed in the laboratory. 35 
events (45% of total cases) were reported in Italy, with 
an incidence of 0.02/100000 population [15].
In 2010-2013 period, 60 cases/year (with 20 deaths/
year) were notified in Italy. Mostly belonged to unvacci-
nated elderly or to elderly that did not performed boost-
er, with a reduction of 91.4% compared to pre-vaccine 
era  [16]. Lack of pediatric vaccination or booster dos-
ages has been related to the higher disease incidence in 
population aged  >  64 years. Anti-Tetanus vaccination 
basal cycle is followed by multiple boosters to the adult 
age, when a booster dosage must be repeated every 10 
years. The importance of boosters against Tetanus is due 
to antibodies levels decline over years and to the time 
needed for antibodies production in the period between 
infection and death [17].
In 2001-2010 period 2 cases of pediatric Tetanus 
(age < 14 years) were notified; successively no pediatric 
cases were reported until June 2017, when 2 cases were 
notified, the first in Sardinia and the second in Piedmont; 
both child were not immunized [18].
Pertussis
Pertussis is a very contagious disease that can occur in 
every ages, but it’s more serious in newborns and in-
fants [19]. Within this age, hospitalization rates due to 
complications as apnea, seizures and pulmonary hyper-
tension are higher; fatality rate can reach 1%. Complica-
tions and death risks are higher in pre-term born com-
pared to term-born [20, 21].
Currently, Pertussis is the vaccine-preventable infectious 
disease most frequent in high-income countries. Its real 
impact is hardly evaluable and scarcely perceived by 
population and even by health workers [22].
From 1999 to 2009 in Italy a decrease in Pertussis cases 
trend was reported, thanks to high vaccine coverage. 
However, Pertussis is probably underestimated, espe-
cially in adolescents and young adults, due to the milder 
clinical presentation and the scarce usage of laboratory 
testing. Among those subjects, parents represent the 
main source of infection for children, in which the dis-
ease can be more severe [23, 24].
In Italy, about 500 cases/year have been notified from 
2011 to 2015 [25]. Hence, compared to the pre-vaccine 
era, Pertussis incidence has a 97.6% reduction; this re-
sult was also achieved thanks to hexavalent vaccine con-
taining Pertussis antigens (Tab. I).
Since both natural and vaccine-acquired immunization 
period against Pertussis is time-limited, it’s pivotal to 
per-form booster dosages in the two cases. In fact, al-
though clinical manifestations are milder as individuals 
grow, every subject can infect newborns, in a time before 
their acquired immunity reaches protective levels. Con-
sequently, as planned in the PNPV paper, it’s essential 
to provide a booster with DTaP-IPV in pre-school age, a 
booster with dTap-IPV in adolescence age and a booster 
with dTap every 10 years in adult age [26].
Cocoon strategy was proposed in order to reduce new-
borns infections. It consists of a booster administration 
in every potential newborn contacts.
Recent recommendations made by Italian experts, in 
accordance with WHO, and based on scientific stud-
ies, demonstrate that the best cost-effective interven-
tion in newborns Pertussis prevention is the vaccina-
tion with dTap vaccine in the pregnant woman, ideally 
in the third trimester: doing so, maternal antibodies 
will be transmitted to the fetus and can protect the 
newborn in the window time from the birth to the first 
vaccination [27].
Poliomyelitis
Poliomyelitis (polio) is an infectious disease burdened 
with a severe prognosis. The main risk in polio is a 
nonreversible flaccid paralysis, affecting especially 
pediatric population. The sole option to prevent Polio-
myelitis consequences is vaccination. The Global Polio 
Eradication Initiative contributed to reduce over 99% 
of the global Poliomyelitis incidence. Europe was de-
clared polio-free in 2002. The last case of polio was 
reported in Turkey in 1978, while 3 cases of polio were 
reported in Bulgaria in 2001, belonging to Rom chil-
dren from India; in that last context, autochthonous 
transmission was stopped [28].
In Italy, thanks to vaccination (mandatory from 1966), 
the last Poliomyelitis case was reported in 1982. Still, 
in order to reach Poliomyelitis eradication, it’s pivotal 
to carry on the IPV (Inactivated Poliovirus Vaccine) vac-
cination program, since as long as a single infected child 
is present, every child in the world is potentially suscep-
tible [29-31]. In fact, even now it’s important to maintain 
high antibodies levels since the risk of importation, and 
the consequent transmission, is present: Poliomyelitis is 
still endemic in Afghanistan and Pakistan [32].
Hepatitis B
Worldwide, 257 million people are Hepatitis B virus 
(HBV) chronic carriers. Chronicity risk is greater es-
pecially if the HBV infection is precocious: risk rate is 
90% in birth-infected children, 30-50% in infected chil-
dren less than 4 years old, 1-10% in the population of 
age > 4 years [33].
Most European countries provide vaccination against 
HBV infection. Italy was a paradigm since in 1991 it es-
tablished anti-HBV vaccination as mandatory for every 
new born and for 12-years-old children [34, 35].
Trends’ analysis concerning case numbers in the period 
1985-2016 shows a significant decline from 1991. Inci-
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dence decline was related especially to age 15-24 years, 
due to newborns and 12-years-old children vaccina-
tion [36]. Thanks to this intervention, Hepatitis B inci-
dence had a 86% reduction and chronic carriers preva-
lence had a reduction from 3% to less than 1% [16, 37]. 
This decline is extremely important, since Hepatitis B 
is one of the leading cause of liver cirrhosis and liver 
cancer, whose diagnosis is 10 years late after infection. 
At a distance of 20 years from the introduction of the 
anti-HBV vaccination, a significant decline in the case 
numbers of Hepatitis B associated liver cirrhosis and 
liver cancer is evident [38].
Over the past five years, 19% of HBV acute infec-
tions regarded non-Italian subjects arriving from HBV 
endemic regions, as East Europe (9% of overall HBV 
notified cases to the Italian Integrated Epidemiological 
System of Acute Viral Hepatitis [SEIEVA]) and Africa 
(4,9% of cases) [39].
HaemopHilus influenzae type b
Hib could be cause of severe and invasive diseases as 
meningitis, sepsis, pneumonia. Hib epidemiology is not 
easy to define, since in several cases a timely laborato-
ry confirmation is not made [40]. In 2007-2014 period 
0.6 cases/100000 population/year were notified in Eu-
rope. Most of these cases was related to younger sub-
jects: incidence was 23.4 cases/100000 newborns [41].
In Italy, the introduction of the vaccination against Hib 
led to 91.3% disease incidence reduction compared to 
pre-vaccine era. Also hospitalization rates due to Hib-
disease halved compared to pre-vaccine era, as de-
scribed in a recent Italian study [42]. Nevertheless, con-
comitantly with vaccination coverage decline, severe 
invasive Hib disease occurred recently in children less 
than 2 years old [42-44].
Currently available hexavalent vaccines
The first combined vaccines were bivalent, with Diph-
theria and Tetanus antigen (DT o dT); later Pertussis an-
tigens were included thus forming the trivalent DTwP 
and dTaP vaccines, containing the inactivated Bordetella 
Pertussis and acellular antigenic components. Hexa-
valent combined vaccines, obtained with the antigens 
mentioned above and in addition polio, Hepatitis B, 
Hib antigens, are available for over 15 years. In Italy, as 
other countries in Europe, hexavalent vaccines are the 
most frequently used vaccine for the immunization of 
infants and toddlers against Diphtheria, Tetanus, Per-
tussis, Hepatitis B, Poliomyelitis and disease caused by 
Hib [45, 49]. 
Currently in Italy, three hexavalent combination vac-
cines are available: Infanrix Hexa®, used since 2000; 
Hexyon®, since 2013; and Vaxelis®, recently authorized.
Their characteristics, described in the Summary of Prod-
uct Characteristics (SPC) documents, are summarized in 
Table II [46-48].
Immunogenicity of antigenic components: 
focus on Pertussis, Hepatitis B, Hib
Although different in composition, the three vaccines 
have comparable immune response, resulting protec-
tive against the 6 target diseases. The immunogenicity 
of hexavalent vaccines has been extensively studied and 
comparative clinical trials have been carried out: in par-
ticular, the studies conducted with the 2  +  1 schedule 
reproduce a vaccination scheme similar to the one in 
current vaccination schedule of the PNPV, both for the 
age of use both for the co-administration with anti-pneu-
mococcal and anti-rotavirus vaccines [49, 50].
In these studies, the responses to each antigen were 
evaluated using pre-established standard seroprotec-
tion correlates as concentration and antibody titers to be 
achieved in order to assert that the vaccine has deter-
mined antibody protection (seroprotection). 
In the case of Pertussis antigens, for which a seropro-
tection indicator is not available, the response to the 
vaccine is evaluated considering the concentrations of 
specific antibodies produced after vaccination that are 
higher than those present before vaccination.
The results demonstrate the high immunogenicity of all 
the antigens included in the three hexavalent products, 
with high percentages of children with seroprotection 
and similar values for each antibody response. Specifi-
cally, the percentage of seroprotected children who re-
sponded to the hexavalent vaccines was non-inferior for 
all anti-body concentrations compared to those of chil-
dren immunized with monovalent or fewer components 
(e.g. dTaP) [3, 4].
Also clinical data of safety, immune response and ef-
fectiveness are available. The results of the follow-up 
of clinical studies confirmed the presence of protective 
antibody titers. Effective protection up to the age of the 
dTaP-IPV booster has been demonstrated, for Hepati-
tis B antibody titers were at protective levels up to the 
age of pre-adolescence, guaranteeing protection against 
the risk of transmission in adolescents and adults. In ad-
dition, epidemiological surveillance programs conduct-
ed in several countries such as Sweden, Denmark and 
Germany, on pathologies such as Pertussis and Hib, have 
confirmed the effectiveness of hexavalent vaccines.
These information are reported in the SPC of the two 
long-standing hexavalents authorized, Infanrix Hexa® 
and Hexyon®, and will be available in a few years for 
Vaxelis®, that have the most recent authorization.
Pertussis
All vaccines combined with acellular components (aP 
acellular Pertussis) contain Pertussis toxoid (PT). The 
other antigenic components of Bordetella Pertussis, 
sometimes included, are: filamentous haemagglutinin 
(FHA), pertactin (PRN) and fimbriae types  2 and 3 
(FIM). Pertussis vaccines are different in the formula-
tion, combination and concentration in micrograms of 
the individual components, and also in the production 
methods used, such as the detoxification and purifica-
tion. Therefore, the comparison between different aP 
vaccines cannot be based only on the number of antigen-
A. ORSI ET AL.
E112
ic components contained, also because the contribution 
to immune protection by each anti-gen is not completely 
clear [26].
The essential component is PT, present in all aP vac-
cines, and directly responsible for the development of a 
protective immune response following vaccination.
The FHA it is the antigen that over time is less mutated 
genetically, unlike the PRN whose mutations led to the 
diffusion of pertactin-resistant strains.
There is no evidence on the contribution of immune pro-
tection given by the fimbriae in the newborn, while it 
seems they may play a role when contained in the boost-
er vaccines for the adult [26].
Moreover, it is well known that even the natural infection 
with Pertussis, which obviously contains “all the compo-
nents”, is able to induce permanent immunity [24, 26].
Although no Pertussis or serologic protection indica-
tor is available for Pertussis, all aP vaccine antigens 
present in hexavalent vaccines have shown high im-
munogenicity in comparative clinical studies (both 
between hexavalent and both combined vaccines with 
fewer components) in terms of the presence of higher 
antibody levels after vaccination compared to the pre-
vaccination serological test [51].
Several evidences have clearly shown how preven-
tion and control of Pertussis are based on the adoption 
of a vaccination schedule that includes, in addition to 
primary vaccination in the newborn, booster in child-
hood, adolescence and adulthood (every 10 years), and 
on reaching and maintaining high coverage, regardless 
of the employed aP vaccine and the number of compo-
nents contained. In particular, in Denmark, where an aP 
vaccine with only PT component has been used for over 
15 years, the disease has been well controlled and no 
outbreaks have occurred  [52, 53]. Also in Sweden, af-
ter 19 years of epidemiological surveillance, Pertussis is 
effectively controlled throughout the nation, regardless 
of the type of vaccine used, with one or more compo-
nents [54].
As underlined by the WHO Pertussis technical group 
(WHO SAGE Pertussis Working Group), the key point 
in the control of the pathology is the achievement of 
high vaccination coverage and a schedule with adequate 
timing for the childhood and booster in adulthood [55]. 
The same consideration are described by the American 
Society of Pediatrics and the CDC in the 12th edition of 
the Pink Book, as well as in the last WHO Pertussis Vac-
cines Position paper 2015: a summary of recommenda-
tions and evidences of use of the aP vaccines is reported 
in Table III.
Hepatitis B
The current Hepatitis B vaccines, both monovalent 
and combined, contain the HBV virus surface antigen 
(HBs), produced in yeast cells by recombinant DNA 
technology. In the case of hexavalent vaccines, the 
yeast cells used are Hansenula polimorpha and Saccha-
romyces cerevisiae: all HBs antigens have been shown 
to be highly immunogenic, although the production 
processes differ in the cell line used.
In the registered clinical trials, high seroprotection rates 
were detected in vaccinated children, with overlapping 
results in the comparison between hexavalent vaccines 
and monovalent anti-Hepatitis B vaccine (anti-HBs ti-
tre ≥ 10 mIU/mL) [49, 50]. Furthermore, in the clinical 
trials follow-up up to pre-adolescence age, anti-Hepatitis 
B antibodies result at highly protective levels in response 
to the administration of a challenge dose, with impor-
tant implications for long-term memory and protection 
against possible future infections  [46,  47,  59]. Further 
Tab. II. Summary of currently available hexavalent vaccines characteristics.
Infanrix Hexa® [46] Hexyon® [47] Vaxelis® [48]
Hib -PRP
10 µg
Conjugated to Tetanus toxoid
12 µg
Conjugated to Tetanus toxoid
3 µg
Conjugated to Meningococcal protein 
Pertussis
PT 25 µg







FIM type 2,3: 5 µg
Diphtheria toxoid 
Not less than 30 UI
*mean value
Not less than 20 UI
*lower limit CI 95%
Not less than 20 UI
*lower limit CI 95%
Tetanus toxoid Not less than 40 UI Not less than 40 UI Not less than 40 UI
IPV Polio
Poliovirus inactivated  
type 1, 2, 3
Poliovirus inactivated  
type 1, 2, 3
Poliovirus inactivated
type 1, 2, 3
Hepatitis B - HBsAg
produced in 
Saccharomyces cerevisiae Hansenula polymorpha Saccharomyces cerevisiae
Ready to use No Yes Yes
Co-administration  Yes Yes Yes
Preterm Yes Yes Yes
Minimum age Not specified 6 weeks 6 weeks
Maximum age No limits No limits No limits
Follow-up studies of 
antibodies persistence
Yes Yes Not available
Effectiveness results Yes Yes Not available
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studies on vaccinations for Hepatitis B have shown that, 
after the primary vaccination during the first year of life, 
protective antibody levels are maintained until adoles-
cence age. Therefore, thanks to the vaccines used up to 
now, including the hexavalents, it is not necessary to ad-
minister a booster for Hepatitis B in the general popula-
tion, while a booster dose may be necessary in those at 
risk and in non-responders [60, 61].
HaemopHilus influenzae type b
In the currently available hexavalent vaccines registra-
tion studies, the immunogenicity of the Hib vaccine was 
assessed by measuring serum IgG antibodies against the 
PRP capsular antigen. The thresholds set for short- and 
long-term protection are, respectively,  ≥  0.15  μg/mL 
and ≥ 1 μg/mL. Considering these as reference values, 
the responses against the PRP antigen of Hib have re-
corded high levels of seroprotection in children vacci-
nated with the hexavalents in use [49, 50].
Furthermore, the efficacy of the Hib vaccine is support-
ed by various evidences deriving from national surveil-
lance systems that monitor the incidence of cases of Hib 
disease and evaluate the trends before and after intro-
duction of vaccination. In Germany, a population-based 
system that integrated hospital admissions surveillance 
and molecular laboratory diagnosis allowed to assess 
the impact of anti-Hib vaccination after the introduction 
of tetravalent and pentavalent products, respectively in 
1996 and 1998. The first surveillance data for the two-
year period 1998-1999 showed that the number of cases 
of Hib disease in children aged 0-5 ranged from 28 to 
13  [62]. Subsequently, data related to a longer period 
(August 2000 - December 2004) made it possible to es-
timate the efficacy of the vaccine in relation to the doses 
administered: the effectiveness of the Hib vaccine was 
96.7% (95% CI: 87.7-99.1) for the cycle complete pri-
mary, and 98.5% (95% CI: 94.5 to 99.6) for the booster 
dose. Estimates of efficacy of the anti-Hib component 
in hexavalent vaccines did not show significant differ-
ences compared to combined tetra and pentavalent vac-
cines [63].
Regarding Italian region, before the introduction of uni-
versal vaccination against Hib, the incidence of invasive 
disease caused by Hib in children aged less than 5 years 
increased from 2.5/100.000 in 1994 to 4.5/100.000 in 
1998, a trend most likely due to the implementation of 
active surveillance for the invasive disease from Hib 
based on laboratory data, implemented at that time in 
some Italian regions. Since 1999, after the introduction 
of anti-Hib vaccination with 2 + 1 schedule, an excellent 
control of the disease has been registered, underlined by 
the reduction in hospitalization rates due to invasive dis-
ease [42].
Co-administration with other vaccines
The safety and immunogenicity of hexavalent vac-
cines do not change significantly when co-administered 
with other vaccines included in the child’s vaccination 
schedule  [64]. Clinical studies of the three hexavalent 
products demonstrated elevated immunogenicity and 
safety standards of the 2  +  1 hexavalent schedule co-
administered with anti-pneumococcal and anti-rotavirus 
vaccines  [6, 48, 49]. Further clinical studies have also 
confirmed the co-administration with vaccines such as 
anti-meningococcal conjugate, anti-measles, mumps, 
rubella and anti-varicella vaccines. The indications for 
all possible co-administrations are reported in the rela-
tive SPC [46-48].
In general, as recommended in the CDC guide on co-
administrations, all vaccines may be administered in the 
same session, without any limitation in the number of 
vaccines administered (alternating sites for subsequent 
injections), unless reported in SPC [65, 66].
Tab. III. Summary of recommendations and evidences of use of the aP vaccines.
Plotkin S et al. 2013 [56]
Surveillance programs demonstrate the efficacy of each aP vaccine in achieving 
excellent pPertussis control
WHO 2016 [57]
Long-term national surveillance studies conducted in Sweden and Denmark, where 
10 2-component vaccines are also used, showed high levels of effectiveness in 
preventing Pertussis regardless of the antigenic content of the various aP vaccines 
used. All polyvalent aP vaccines showed high levels of effectiveness in preventing 
pertussis independently of aP in these contents
WHO SAGE Working Group 2014 [55] 
There is no evidence to conclude that one type of aP vaccine is superior to others. The 
available data reinforce the importance of achieving and maintaining high coverage 
and implementing appropriate vaccination schedules
CDC Pink Book 2015 [19]
The efficacy of the vaccines aP it’s variable between 80% and 85%, the respective 
confidence intervals of these overlap each other, suggesting that none of the aP 
vaccines is significantly more effective than other
American Academy of Pediatrics 1997 [58] Although the different aP vaccines available differ in their formulation of Pertussis 
antigens, their efficacy is similar
Gabutti et al. 2015 [26]
The use of the current polyvalent vaccines with aP allowed the achievement and 
maintenance of high vaccine coverage that, regardless of the type of vaccine and 
the number of AP in these contents, is the key factor for successful vaccination 
interventions against Pertussis
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Safety of hexavalent vaccines
Vaccines can be considered among the most controlled 
and safe pharmaceutical products. Before marketing 
authorization and introduction into immunization pro-
grams, they are subjected to different stages of safety 
and efficacy assessment. Once authorized, the produc-
tion processes are subject to accurate and continuous 
checks and the presumed adverse events are constantly 
monitored and analyzed, in order to guarantee to the 
population safe and high quality vaccines. Furthermore, 
the production of vaccines is controlled in compliance 
with standards indicated by international organizations 
such as the European Medicines Agency (EMA) and 
the WHO.
Although the vaccines currently used in immunization 
programs are safe and effective, they, like all drugs, are 
not exempt from possible adverse events, although rare, 
after vaccination. An AEFI is defined as any adverse 
clinical event that occurs following the administration of 
a vaccine and which does not necessarily have a causal 
relationship with the use of the vaccine [67].
The results of the safety reports analyzes collected in the 
clinical studies on hexavalent products showed good tol-
erability of these vaccines, confirmed both by the study 
follow-up and by the phase IV post-marketing surveil-
lance systems. The results of the safety of hexavalent 
vaccines are included in the relative SPC [46-48].
In general, a higher but not clinically significant rate of 
fever and local symptoms (from mild to moderate, and in 
any case transient) was recorded compared to vaccines 
with fewer components. However, the use of combined 
hexavalent vaccines is overall safer because, by subject-
ing the child to a single injection instead of six, the total 
frequency of these reactions is reduced, which also oc-
curs for co-administration with other vaccines for chil-
dren [5, 68, 69].
Detailed data on post-marketing surveillance of vac-
cines in Italy derive from the latest AIFA report, which 
summarizes the post-marketing surveillance activities 
on vaccines conducted in Italy in 2016 [70]. Reports of 
suspected ad-verse reactions to hexavalent vaccine, col-
lected through the National Pharmacovigilance Network 
in 2016 were 1’127, of which 670 (59.4%) occurred in 
the period from January 1 to December 31, 2016. The 
serious reactions were 188, 16.7% of suspected reports 
included in the National Pharmacovigilance Network. 
Most reports (No. 845, 75%) refer to the simultaneous 
administration of hexavalent and other vaccines (in par-
ticular the pneumococcal vaccine), following the co-ad-
ministration provided by the vaccination schedule.
As with other vaccines, most reactions are mild and 
transient. The ten reactions more frequently reported 
after hexavalent vaccine in 2016 in Italy are described 
in Table IV.
As regard to Sudden Infant Death Syndrome (SIDS), the 
Report states that there is no evidence of causal relation-
ship between exposure to vaccines and SIDS, and that 
the incidence of this is the same both in the presence 
and both in the absence of vaccination. A short distance 
between the SIDS and the vaccination does not imply, 
therefore, any cause-effect relationship.
Further support for the safe use of vaccines is the Guide 
to contraindications to vaccinations, including the hexa-
valent one, in which the real contraindications are distin-
guished from the false ones [71] (Tab. V).
Practical considerations
Summary of Product Characteristics: 
clarifications on terminology
The terminology used in the summary of product char-
acteristics, that is sometimes a source of interpretative 
confusion, has been recently deepened and clarified in a 
document of the “Calendario per la Vita” Italian board, a 
panel of experts belonging to the main scientific society 
engaged in vaccination and public health [72].
One of the key points is the paragraph 4.1 which estab-
lishes indications of the use of the vaccine, even with a 
medical point of view. Section 4.2 indicates the dosage 
and method of administration of the vaccines. The other 
sections contain specifications on population groups in 
which efficacy and safety studies were performed, data 
on interactions with other drugs (section 4.5) and phar-
macodynamic properties (section 5.1). The information 
contained in these paragraphs should not be confused 
with the indications of the vaccine1. For example, with 
regard to the age of employment, hexavalent vaccines 
are given “starting at 6 weeks of life”, without an up-
per limit of use. Considering that they contain a dose 
of “pediatric” antigens, even if this indication is not 
included in the technical data sheet, their use is rec-
ommended up to 7 years of age. Obviously, both the 
vaccines and the drugs used in the therapeutic field are 
usually studied in the age groups where their greatest 
use is expected. However, the fact that a vaccine has 
safety studies up to 24/36 months, for example, does 
not preclude its use in older age groups, as it is also 
reported in the indications for hexavalent vaccines and 
appropriately specified also by the European Medi-
cines Agency (EMA).
Tab. IV. First ten reactions reported in order of frequency after ad-
ministration of hexavalent vaccine in 2016 in Italy.






Swallow at the time of vaccination 55
Erythema at the time of vaccination 51





A further example regards the employment in particular 
groups of children, such as preterm births. In this case, 
although there is no specific indication in paragraph 4.1, 
the administrability is confirmed both by the absence of 
relative contraindications (section 4.3), and by the pres-
ence of specific precautions regarding very premature 
births (section 4.4).
Furthermore, as indicated by AIFA in the Drugs In-
formation Bulletin, the use in clinical practice of 
drugs, or even vaccines, already registered but used 
in a manner not in accordance with the summary of 
the characteristics of the drug is defined “off-label” 
authorized product  [73]. Therefore, also taking into 
account the current legislation that regulates the off-
label use of medical products and compliance with the 
authorized therapeutic indications (Article 3 of Leg-
islative Decree 17 February 1998, converted into Law 
of 8 April 1998), we can conclude that all and three 
hexavalent vaccines can be used up to 7 years of age 
and can be used in premature babies [74]. In essence, 
the use of hexavalents in premature babies and in all 
subjects up to 7 years is to be considered as “on-label” 
use, adequate to what is prescribed in the summary of 
product characteristics.
Schedule and specific dosage
The results obtained in the studies conducted with 2 + 1 
schedule, with administrations at the 3rd, 5th and 11th -13th 
month of age, showed that the antibody responses reach 
high levels of seroprotection for all the antigens of the 
three hexavalents [49, 50].
The two long-standing hexavalents authorized and 
used with 2 + 1 schedule have been shown to prevent 
the six diseases for which they determine immunity, 
feedback obtained from the follow-up of clinical stud-
ies and the anal-ysis of epidemiological surveillance 
programs [46-48].
Age of employment and recovery  
of defaulters
All hexavalent vaccines are indicated in all children 
from 6 weeks of age and, as described in the summary 
of product characteristics, there is no limit of upper age.
The recommendations of the “Calendario per la Vita” 
board for the recovery of vaccinations in non-compliant 
children have been reiterated by the Ministry of Health: 
the use of hexavalent vaccines is recommended up to 7 
years of age. Both the board and the Ministry of Health 
recommend to the healthcare workers to propose to the 
parents, as the first choice, the administration of the hex-
avalent vaccine, as it allows to reduce to a minimum the 
number of sessions and the number of administrations 
and to minimize the possible side effects [72, 75].
The recommendations of the board and the Ministry of 
Health are in line with those contained in the vaccina-
tion position paper of the Italian Society of Pharmacol-
ogy (SIF), drawn up together with the Italian Society of 
Pediatrics (SIP), with the Italian Society of Preventive 
Medicine and Public Health (SITI), wih the Federation 
of Family Pediatricians (FIMP) and with the General 
Practitioners (FIMMG). The document, approved by the 
National Institute of Health, recommends the use of vac-
cines containing antigens in pediatric concentration up 
to 7 years, such as hexavalent vaccines.
The ECDC and the WHO also recommend the use of 
pediatric vaccines, such as hexavalents, in older chil-
dren, in line with EMA indications on these type of vac-
cines [76, 77].
Therefore, the use of hexavalent vaccines is supported 
by: (i) the evidence of the registration studies (efficacy 
and safety studies) conducted in the population groups 
that include the age groups in which their greatest use 
is expected; (ii)  the experience of vaccines combined 
with similar formulation, such as tetravalents, already 
studied and indicated up to higher ages (DTaP-IPV up 
to 12 years of age); (iii) pharmacovigilance studies and 
Tab. V. Contraindication (true or false) and precautions for the use of hexavalent vaccine.
Contraindications Precautions False contraindications
Severe allergic reaction 
(anaphylaxis)  
after administration  
of a previous dose
Severe allergic reaction 
(anaphylaxis)  





not attributable to another 
cause within seven days  
of administration of a 
previous dose of hexavalent  
until clarification  
of the cause  
or stable disease
Encephalopathies and encephalopathies 
with seizure of unknown aetiology, 
including West syndrome 
Guillain-Barré Syndrome and related 
syndromes within 6 weeks of administration 
of a previous dose of vaccine
Severe or moderate acute illness, with or 
without fever
Peripheral neuritis after the administration 
of a previous dose
Immediate generalized urticaria after the 
administration of a previous dose
Extreme prematurity
Severe latex allergic reaction  
(for products containing latex in the 
syringe)
Immunocomplexing (arthus) after 
administration of a previous dose
Positive anamnesis for febrile seizure
Neurological disorders (well-controlled seizures, 
cerebral palsy, developmental delay)
Episode of hypotonia-hyporesponsiveness within 
48 hours after administration of a previous dose of 
hexavalent
Hyperpyrexia after a previous dose of hexavalent
Persistent and uncontrolled crying for more than 3 
hours after previous administration of hexavalent
Family history of SIDS
Non-extreme prematurity
History of local reaction extended after previous 
dose
Clinical history of pertussis
Family history of convulsions
Family history of adverse events after administration 
of aP or wP
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post-marketing surveillance; (iv)  the recommendations 
of scientific societies, international organizations and 
the Ministry of Health.
Vaccination in preterm births
The WHO defines as a preterm the child born before 
the 37th week of gestation; moreover, prematurity is 
distinguished in mild, medium and severe according 
to the gestational age at birth [78].
In the vaccination schedule of the PNPV, no differ-
ence is made between term and premature births, indi-
cating that all children are vaccinated with hexavalent 
from the 3rd month of life [9].
The results of a recent literature review have con-
firmed that all monovalent and combined vaccinations 
give sufficient protection guarantee when adminis-
tered in preterm births, with the only exception of the 
monovalent Hepatitis B vaccine which, when given 
at birth (born from HBsAg positive mothers), gives a 
lower immune response and should be repeated at one 
month of life to obtain adequate protection. Sufficient 
and protective anti-HBs concentrations are produced 
by preterm infants at the completion of the hexavalent 
vaccination schedule at 9-12 months of age [79].
Furthermore, the results of epidemiological surveil-
lance of invasive Hib disease in Tuscany in 2007-
2017, the period in which Infanrix Hexa® was first 
used and after Hexyon® in all children, including pre-
term births, have shown that both hexavalent vaccines 
are safe and effective, since no case of illness was 
registered among the children vaccinated in the study 
period (except for a child with a congenital antibody 
defect, unable to produce antibodies to protective lev-
els) [80].
The three hexavalent vaccines do not have a specific 
indication in point 4.1 of the summary of product char-
acteristics relating to preterm births. Infanrix Hexa® 
and Vaxelis® summary of product characteristics re-
port clinical data on premature delivery, although on a 
limited number of newborns. Hexyon® does not have 
specific data on preterm births in the data sheet, but 
data on use and effectiveness were collected in an epi-
demiological surveillance program in Tuscany.
As proof of the fact that the use of the three hexava-
lent vaccines fully respect the authorized therapeutic 
indications, the summary of products characteris-
tics of the three vaccines show the same informa-
tion on the “very preterm” born in point 4.4 (Special 
warnings and precautions for use), born before the 
28th week and with a history of respiratory failure. In 
these children, in fact, considering the potential risk 
of apnoea onset, it is necessary to monitor the respira-
tion in the hospital for 48-72 hours after administra-
tion. Because the benefit of vaccination is high in this 
group of newborns, vaccination should not be stopped 
or postponed [46-48].
These precautions are valid for all pediatric vaccines 
that can be administered in newborns and for which 
preterm use, including very premature ones, is also 
expected.
Therefore, all hexavalent vaccines can be used in pre-
term births, with a 2 + 1 schedule and respecting the 
same timing of term births, without delaying immu-
nization.
Vaccination in the births  
of a positive HBsAg mother
The available hexavalent vaccines report in the sum-
mary of product characteristics the possibility of use 
in children born to HBsAg positive mothers [46-48]. 
The 2017-2019 PNPV schedule includes monovalent 
vaccination for Hepatitis B at birth and at 30 days of 
life. In these children, the vaccination series continues 
with the 2 + 1 schedule of the hexavalent [9]. As dem-
onstrated by a review of clinical trials, this scheme 
ensures the production of protective antibody concen-
trations in all children, including preterm births [79].
Interchangeability
Given the existence of combined vaccines containing 
slightly different components, practitioners often ask 
them-selves how to continue the cycle if the previous 
vaccine given is unknown or is no longer available at the 
time of the next dose.
In general, it is preferable to continue the vaccination 
schedule with the same product with which immuniza-
tion was started [81]. Although it is possible, if not ex-
plicitly contraindicated in the data sheet, to use a hexava-
lent vaccine different from that used in the previous dose 
of the schedule, it is appropriate that safety and efficacy 
data are available, and that this mode of use is described 
in summary of products characteristics [5, 46-48].
Actually, only the hexavalent Hexyon® possesses these 
requirements, and the related methods of use are de-
scribed in summary of products characteristics.
Preparation method:  
pre-filled syringe or to be reconstituted
While Hexyon® and Vaxelis® are available in fully-liquid 
formulation, in pre-filled and ready-to-use syringe, In-
fanrix Hexa® requires, prior to the administration, the 
reconstitution in the main syringe of the Hib antigen, 
contained in-stead in a vial [46-48].
Several studies have compared these types of vaccines, 
with results of a reduction of about 5 times the risk of 
possible errors in the preparation and halving of the time 
of administration for those in formulation in pre-filled 
syringe compared to vaccines that require a reconstitu-
tion process [82-85].
Conclusions
In consideration of what has been described and evoked 
by the literature and by the registration studies of the 
hexavalent vaccines, together with the recent recom-
mendations on their use of the “Calendario per la Vita” 
board, it can be concluded that: (i) combined vaccines 
reduce the number of administrations and therefore the 
frequency of local reactions to the injection site and of 
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crying, as well as reducing the number of visits and ac-
cess necessary for completing the vaccination schedule; 
(ii) clinical studies have shown that the three hexavalent 
vaccines have a high immunogenicity and safety profile; 
(iii) hexavalent vaccines may be co-administered in the 
same vaccination session with pneumococcal and anti-
rotavirus vaccines, as foreseen in the PNPV calendar; 
(iv) hexavalent vaccines can be administered in preterm 
births with a 2 + 1 schedule, without delaying the start 
of the immunization cycle; moreover, for the very pre-
term births (ie born before the 28th week of gestation) 
and with respiratory insufficiency, the precautions for 
use described in the summary of product characteris-
tics must be followed; (v) two hexavalent vaccines have 
antibody persistence data in summary of product char-
acteristics, demonstrated by follow-up of clinical trials 
(up to 9-11 years for anti-HBs antibodies) and efficacy 
data from epidemiological surveillance programs. For 
the third vaccine, with the most recent authorization, 
the same data will be available in a few years; (vi) all 
hexavalents are highly effective in preventing Pertussis, 
as demonstrated by related surveillance programs; the 
vaccination of the mother during pregnancy is the most 
effective intervention for the prevention of the disease 
in the first months of life; (vii) there are no differences 
in immunogenicity between different antigen formula-
tions; (viii) it is preferable to continue the schedule with 
the same vaccine with which it was started, or that spe-
cific modalities are reported in the summary of product 
characteristics; (ix) the formulation in pre-filled syringe 
reduces the risk of possible errors and time of prepara-
tion and administration.
Acknowledgements
The Authors thank Dr. Francesca Butera, Dr. Maria 
Francesca Piazza and Dr. Sara Schenone for revising the 
manuscript.
All Authors previously participated in advisory boards 
and expert meetings or were speakers or organizers of 
congresses/conferences on hexavalent vaccines spon-
sored by GlaxoSmithKline Biologicals SA, Sanofi Pas-
teur-MSD, MSD or Sanofi Pasteur.
Authors’ contributions
All Authors have made a substantial contribution to the 
conception, design, analysis and interpretation of data, 
drafting the article and revising it critically for intellectual 
content; all Authors approve the final version submitted to 
the Journal of Preventive Medicine and Hygiene.
References
[1] Agenzia Italiana del Farmaco. Vaccinazioni come strumento 
di sanità pubblica: le conclusioni del Consiglio UE. www.aifa.
gov.it/content/vaccinazioni-come-strumento-disanit%C3%A0-
pubblica-le-conclusioni-del-consiglio-ue.
[2] Skibinski D, Baudner B, Singh M, et al. Combination vaccines. 
J Global Infectious Diseases 2011;3:63.
[3] Decker MD. Principles of pediatric combination vaccines and 
practical issues related to use in clinical practice. Pediatr Infect 
Dis J 2001;20(Suppl 11):S10-8.
[4] Maman K, Zöllner Y, Greco D, et al. The value of childhood 
combination vaccines: from beliefs to evidence. Hum Vaccin 
Immunother 2015;11:2132-41.
[5] Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, et al. New 
perspectives for hexavalent vaccines. Vaccine 2017. http://
dx.doi.org/10.1016/j.vaccine.2017.06.063.
[6] Vidor E, Soubeyrand B. Manufacturing DTaP-based combi-
nation vaccines: industrial challenges around essential public 
health tools. Expert Review of Vaccines 2016;15:1575-82.
[7] Plotkin S, Robinson J, Cunningham G, et al. The complex-
ity and cost of vaccine manufacturing - an overview. Vaccine 
2017;35:4064-71.
[8] Rizzo C, Filia A, Rota MC (ISS Epicentro). Obbligo vaccinale: 
cos’è e perché è importante. www.epicentro.iss.it/temi/vaccina-
zioni/ObbligoVaccinale.asp.
[9] Ministero della Salute. Piano Nazionale Prevenzione Vaccinale 
2017-2019.
[10] Diphtheria - Annual Epidemiological Report for 2015. https://
ecdc.europa.eu/sites/portal/files/documents/AER_for_2015-
diphtheria.pdf.
[11] ISS Epicentro. Difterite, aggiornamenti. www.epicentro.iss.it/
problemi/difterite/aggiornamenti.asp.
[12] ISS Epicentro. Difterite in Italia. www.epicentro.iss.it/proble-
mi/difterite/DifteriteItalia2017.asp.
[13] Zakikhany K, Neal S, Efstratiou A. Emergence and molecular 
characterisation of non-toxigenic tox gene- bearing Corynebac-
terium diphtheriae biovar mitis in the United Kingdom, 2003-
2012. Euro Surveill 2014;19:20819.
[14] Monaco M, Mancini F, Ciervo A, et al. La difterite: è ancora 
una malattia da sorvegliare? Notiziario dell’Istituto Superiore di 
Sanità 2015:28:3-8.
[15] ECDC. Tetanus, annual epidemiological report for 2015. https://
ecdc.europa.eu/sites/portal/files/documents/AER_for_2015-
tetanus.pdf.
[16] Epicentro. “I vaccini? Funzionano!”. Settimana europea e mon-
diale delle vaccinazioni 2017. www.epicentro.iss.it/temi/vacci-
nazioni/SettimanaVaccinazioni2017.asp.
[17] Filia A, Bella A, Hunolstein C, et al. Tetanus in Italy 2001-2010: 
a continuing threat in older adults. Vaccine 2014;32:639-44.
[18] Epicentro. Tetano. Aspetti epidemiologici. In Italia. www.epi-
centro.iss.it/problemi/tetano/EpidItalia.asp.
[19] Centers for Disease Control and Prevention. Epidemiology and 
Prevention of Vaccine-Preventable Diseases. Hamborsky J, 
Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health 
Foundation, 2015.
[20] Haberling DL, Holman RC, Paddock CD, et al. Infant and ma-
ternal risk factors for pertussis-related infant mortality in the 
United States, 1999 to 2004. Pediatr Infect Dis J 2009;28:194-8.
[21] Stefanelli P, Buttinelli G, Vacca P, et al. Severe pertussis infec-
tion in infants less than 6 months of age: clinical manifesta-
tions and molecular characterization. Hum Vaccin Immunother 
2017;13:1073-7.
[22] Berbers GAM, de Greeff SC, Mooi FR. Improving pertussis 
vaccination. Hum Vaccin 2009;5:497-503.
[23] Fedele G, Carollo M, Palazzo R, et al. Parents as source of 
pertussis transmission in hospitalized young infants. Infection 
2017;45:171-8.
[24] Gabutti G, Rota MC. Pertussis: a review of disease epidemiol-
ogy worldwide and in Italy. Int J Environ Res Public Health 
2012;9:4626-38.
[25] ECDC. Pertussis, annual epidemiological report for 2015. 




[26] Gabutti G, Azzari C, Bonanni P, et al. Pertussis, current perspec-
tives on epidemiology and prevention. Hum Vaccin Immunother 
2015;11:108-17.
[27] Advisory Committee on Immunization Practices (ACIP). Up-
dated recommendations for use of tetanus toxoid, reduced diph-
theria toxoid, and acellular pertussis vaccine (Tdap) in pregnant 
women. MMWR Morb Mortal Wkly Rep 2013;62:131-5.
[28] Bull World Health Organ. Europe to be certified free of polio. 
PMCID 2002;80:688.
[29] ISS Epicentro. Poliomielite. www.epicentro.iss.it/problemi/po-
lio/aggiornamenti.asp.
[30] Ministero della Salute. Poliomielite. www.salute.gov.it/portale/sa-
lute/p1_5.jsp?lingua=italiano&id=117&area=Malattie_infettive.
[31] ISS Epicentro. Vaccini e vaccinazioni. www.epicentro.iss.it/te-
mi/vaccinazioni/ObbligoVaccinaleStoria.asp.
[32] ECDC. Polio, annual epidemiological report ECDC 2016.
[33] Edmunds WJ, Medley GF, Nokes DJ, et al. The influence of age 
on the development of the hepatitis B carrier state. Proc Biol Sci 
1993;253:197-201.
[34] Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C 
in Europe: report from the hepatitis B and C summit conference. 
J Viral Hepat 2011;18(Suppl 1):1-16.
[35] Legge 27 maggio 1991, n. 165. Obbligatorietà della vaccinazio-
ne contro l’epatite virale B. GU n.127 del 1-6-1991.
[36] ISS Epicentro. Epatite virale - aspetti epidemiologici. www.epi-
centro.iss.it/problemi/epatite/EpidemiologiaItalia.asp.
[37] AUSL Modena. Epatite B. La malattia. www.ausl.mo.it/flex/
cm/pages/ServeBLOB.php/L/IT/IDPagina/8125.
[38] Romanò L, Paladini S, Zanetti A. Twenty years of universal 
vaccination against Hepatitis B in Italy: achievements and chal-
lenges. J Public Health Res 2012;1:126-9.
[39] Epicentro. Epatiti virali. Aspetti epidemiologici, Italia. www.
epicentro.iss.it/problemi/epatite/EpidemiologiaItalia.asp.
[40] World Health Organization. Haemophilus influenzae type B. 
Disease burden. www.emro.who.int/health-topics/haemophil-
us-influenzae-type-b/disease-burden.html.
[41] Whittaker R, Economopoulou A, Dias J, et al. Epidemiology of 
invasive Haemophilus influenzae disease, Europe, 2007-2014. 
Emerg Infect Dis 2017;23:396-404.
[42] Martinelli D, Azzari C, Bonanni P, et al. Impact of Haemophilus 
influenzae type b conjugate vaccination on hospitalization for 
invasive disease in children fifteen years after its introduction in 
Italy. Vaccine 2017;35:6297-301.
[43] Istituto Superiore Sanità. Dati di sorveglianza delle malattie 
batteriche invasive aggiornati al 16 novembre 2016. www.iss.it/
binary/mabi/cont/Report_MBI_20161116_v11.pdf.
[44] SIF, SITI, SIP, FIMMG, FIMP. I vaccini e le vaccinazioni. 
www.igienistionline.it/docs/2017/09sif.pdf.
[45] Esposito S, Tagliabue C, Bosis S, et al. Hexavalent vaccines 
for immunization in paediatric age. Clin Microbiol Infect 
2014;20:76-85.
[46] Infanrix hexa, RCP. Disponibile su sito AIFA.
[47] Hexyon, RCP. Disponibile su sito AIFA.
[48] Vaxelis, RCP. Disponibile su sito AIFA.
[49] Vesikari T, Silfverdal S, Jordanov E, et al. A randomized, con-
trolled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent 
vaccine, administered in a 3-, 5- and 11- to 12-month schedule. 
Pediatr Infect Dis J 2017;36:87-93.
[50] Silfverdal S, Icardi G, Vesikari T, et al. A phase III randomized, 
double-blind, clinical trial of an investigational hexavalent vac-
cine given at 2, 4, and 11-12 months. Vaccine 2016;34:3810-6.
[51] Corsello G. La pertosse: una malattia che si sconfigge con ade-
guate coperture vaccinali. RIAP 2017;31(03):24-31.
[52] Hviid A, Stellfeld M, Andersen P, et al. Impact of routine vac-
cination with a pertussis toxoid vaccine in Denmark. Vaccine 
2004;22:3530-4.
[53] Thierry-Carstensen B, Dalby T, Stevner M, et al. Experience 
with monocomponent acellular pertussis combination vaccines 
for infants, children, adolescents and adults - a review of safety, 
immunogenicity, efficacy and effectiveness studies and 15 years 
of field experience. Vaccine 2013;31:5178-91.
[54] Pertussis surveillance in Sweden. Nineteen-year report. www.
folkhalsomyndigheten.se/contentassets/65ed8f6dbdab4999bc3
58fcd9b657e77/pertussis-sweden-nineteen-year-report.pdf.
[55] SAGE Working Group. Report on pertussis vaccines. www.
who.int/immunization/sage/meetings/2015/ april/1_Pertussis_
report_final.pdf.
[56] Plotkin S, Orenstein W, Offit P. Vaccines. 6th ed. Scotland: Else-
vier/Saunders 2013.
[57] World Health Organization. WHO position paper on pertussis 
vaccines 2015. Vaccine 2016;34:1423-5.
[58] American Academy of Pediatrics. Acellular pertussis vaccine: 
recommendations for use as the initial series in infants and chil-
dren. Pediatrics 1997;99.
[59] Bialek S, Bower W, Novak R, et al. Persistence of protection 
against hepatitis B virus infection among adolescents vacci-
nated with recombinant hepatitis B vaccine beginning at birth a 
15-year follow-up study. Pediatr Infect Dis J 2008;27:881-5.
[60] But DY-K, Lai C-L, Limb W-L, et al. Twenty-two years follow-
up of a prospective randomized trial of hepatitis B vaccines 
without booster dose in children. Vaccine 2008;26:6587-91.
[61] European Consensus Group on Hepatitis B immunity. Are 
booster immunisations needed for lifelong hepatitis B immu-
nity? Lancet 2000;355:561-5.
[62] von Kries R, Kalies H, Schmitt HJ. DTPa(+)/Hib combination 
vaccines: the German experience. An Pediatr (Barc) 2003;58(Sup-
pl 5):22-6. www.analesdepediatria.org/en/pdf/13048831/S300.
[63] Kalies H, Grote V, Siedler A, et al. Effectiveness of hexavalent 
vaccines against invasive Haemophilus influenzae type b dis-
ease: Germany’s experience after 5 years of licensure. Vaccine 
2008;12:2545-52.
[64] CDC Pink Book. Immunology and vaccine-preventable diseases. 
www.cdc.gov/vaccines/pubs/pinkbook/downloads/genrec.pdf.
[65] CDC Pink Book. General recommendations on immunization. 
www.cdc.gov/vaccines/pubs/pinkbook/downloads/genrec.pdf.
[66] Immunization Action Coalition. Administering vaccines. www.
immunize.org/askexperts/administering-vaccines.asp.
[67] WHO, HIS, EMP, QSS Causality assessment of adverse event 
following immunization (AEFI): user manual for the revised 
WHO classification. 2013.
[68] Zepp F, Schmitt H, Cleerbout J, et al. Review of 8 years of expe-
rience with Infanrix hexaTM (DTPa-HBV-IPV/Hib hexavalent 
vaccine). Expert Rev Vaccines 2009;8:663-78.
[69] Nunes Madhi S. Review of a new fully liquid, hexavalent vac-
cine: Hexaxim. Expert Opin Biol Therapy 2013;13:575-93.
[70] AIFA. Rapporto sulla sorveglianza postmarketing dei vaccine in 
Italia 2016. www.aifa.gov.it/sites/default/files/Rapporto_Vacci-
ni_2016.pdf.
[71] Gallo G, Mel R, Ros E, et al. Guida alle controindicazioni alle 
vaccinazioni. 5a ed. Roma: Istituto Superiore di Sanità 2017.
[72] Board Calendario per la Vita. Precisazioni del Board del Calen-
dario per la Vita riguardo alla vaccinazione degli inadempienti 
all’obbligo vaccinale.
[73] AIFA, Ministero della Salute. Bollettino d’informazione sui far-
maci: off-label. 2006.
[74] Gazzetta Ufficiale della Repubblica Italiana. Osservanza delle 
indicazioni terapeutiche autorizzate. Art. 3 D.Lgs. 17 febbraio 




[75] Board Calendario per la Vita. Recuperi vaccinali. Indirizzi pro-
cedurali inerenti l’applicazione della Legge 119 del 31 luglio 
2017 sull’obbligo vaccinale per l’iscrizione a scuola.
[76] ECDC. Vaccinations to be offered in the absence of document-




[77] World Health Organization. Recommendations for interrupted 
or delayed routine immunization - summary of WHO Position 
Papers. 2017. www.who.int/immunization/policy/Immuniza-
tion_routine_table3.pdf.
[78] WHO. Preterm birth. Fact sheet. 2016. www.who.int/mediacen-
tre/factsheets/fs363/en/.
[79] Esposito S, Serra D, Gualtieri L, et al. Vaccines and preterm 
neonates: why, when and with what. Early Human Development 
2009;85:S43-5.
[80] Azzari C, Ricci S, Lippi F, et al. Vaccinazione esavalen-
te: nuove evidenze scientifiche e falsi miti da sfatare. RIAP 
2017;31(03):32-39.
[81] Greenberg D, Feldman S. Vaccine interchangeability. Clin Pedi-
atr 2003;42:93-9.
[82] Kumar G, Padhiar A, Carroll S, et al. Estimating the cost impact 
of switching from a vial to a pre-filled syringe mode of admin-
istration for the dTaA-IPV-Hib ‘5-In-1’ vaccine in infants. Value 
in Health 2013;16:A345.
[83] Wiedenmayer K, Weiss S, Chattopadhyay C, et al. Simplify-
ing paediatric immunization with a fully liquid dTPHepB-Hib 
combination vaccine: evidence from a comparative time-motion 
study in India. Vaccine 2009;27:655-9.
[84] Lafuma A, Mara Y. Comparison of the time to prepare contrast 
media injection in CT scan exam with prefilled syringes and 
bottles in 7 European countries. Value in Health 2009;12:A254.
[85] De Coster I, Fournie X, Faure C, et al. Assessment of prepa-
ration time with fully-liquid versus non-fully liquid paedi-
atric hexavalent vaccines. A time and motion study. Vaccine 
2015;33:3976-82.
n Received on May 12, 2018. Accepted on May 30, 2018.
n Correspondence: Andrea Orsi, Department of Health Sciences, 
University of Genoa, "Ospedale Policlinico San Martino IRCCS" 
Teaching Hospital, via A. Pastore 1, 16132 Genoa, Italy - Tel. +39 
010 5552996 - E-mail: andrea.orsi@unige.it
